SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

For the Quarterly Period Ended June 30, 2002March 31, 2003

Or

For the transition period from                             to                             

Commission file number:    000-30975

TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)

(402) 452-5400
(Registrant's telephone number, including area code)

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.  Yes ý    No o

        Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  Yes o    No ý

        As of August 5, 2002,April 30, 2003, the number of shares of common stock outstanding was 23,478,72723,532,049 consisting of 23,973,33124,026,653 shares issued less 494,604 shares of Treasury Stock.

TRANSGENOMIC INC.

INDEX

PART II.    FINANCIAL INFORMATION

Item 1.    Financial Statements

Transgenomic, Inc. and Subsidiaries
Consolidated Balance Sheets (Unaudited)
(In thousands except share and per share data)

The accompanying notes are an integral part of these financial statements.

1

Transgenomic, Inc. and Subsidiaries
Consolidated Statements of Operations (Unaudited)
(In thousands except share and per share data)

The accompanying notes are an integral part of these financial statements.

2

Transgenomic, Inc. and Subsidiaries
Consolidated Statement of Cash Flows (Unaudited)
(In thousands)

The accompanying notes are an integral part of these financial statements.

3

Transgenomic, Inc. and Subsidiaries
Notes to the Consolidated Financial Statements (Unaudited)
(In thousands except share and per share data)

A.    CONSOLIDATED FINANCIAL STATEMENTS

        The accompanying unaudited consolidated financial statements of Transgenomic, Inc. and Subsidiaries (the "Company") have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. In the opinion of management of the Company, all adjustments (consisting of only normal and recurring accruals) have been made to present fairly the financial positions, the results of operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2002 and 2001 are not necessarily indicative of the results to be expected for the full year. Although the Company believes that the disclosures are adequate to make the information presented not misleading, these financial statements should be read in conjunction with the consolidated financial statements for the period ended December 31, 20012002, that are included in the Company's Annual Report on Form 10-K.

        NewStock Based Compensation.

        The Company accounts for its employee stock option grants under the provisions of Accounting PronouncementsPrinciples Board Opinion No. 25,Accounting for Stock Issued to Employee    In June 2001,s, which utilizes the Financial Accounting Standards Board (FASB) issuedintrinsic value method. Accordingly, compensation cost for stock options is measured as the excess, if any, of the deemed fair market value of the Company's common stock at the date of grant over the stock option exercise price. Stock option grants to nonemployees are accounted for using the fair value method of accounting in accordance with Statement of Financial Accounting StandardStandards (SFAS) No. 141,123,Business CombinationsAccounting for Stock-Based Compensation,, and SFAS No. 142,Goodwill and Other Intangible Assets. SFAS No. 141 requires all business combinations initiated after June 30, 2001 to be accounted for using the purchase method. SFAS No. 142 establishes new guidelines for accounting for goodwillBlack-Scholes model.

        The following table illustrates the effect on net loss and other intangible assets and provides that goodwill and other intangible assets with indefinite lives will not be amortized, but will be evaluated for impairment annually. Theloss per share if the Company adopted SFAS No. 142 beginning January 1, 2002. Thehad applied the fair value recognition provisions of SFAS No. 142 also require the completion of a transitional impairment test within six months of adoption, with any impairment treated as a cumulative effect of a change in accounting principle.123,Accounting for Stock-Based Compensation, to stock based employee compensation.

B.    SHORT TERM INVESTMENTS

        The Company has performedhad no short-term investments at March 31, 2003. At December 31, 2002, short-term investments consisted of the transitional goodwill impairment testsfollowing:

        Maturities of short-term investments are due within one year.

4

C.    INVENTORIES

        At March 31, 2003 and has determined that no impairment exists atDecember 31, 2002, inventories consisted of the timefollowing:

D.    OTHER ASSETS

        At March 31, 2003 and December 31, 2002, finite lived intangible assets and other assets consist of adoption of SFAS No. 142. A reconciliation of previously reported net income and earnings per share to the amounts adjusted for the exclusion of goodwill amortization follows:following:

        Amortization expense for intangible assets was $78$218,000 during the six monthsquarter ended June 30, 2002.March 31, 2003. The Company expects amortization expense for intangible assets to be $400approximately $564,000 for the remainderbalance of fiscal 2002 and approximately $800 in fiscal 2003, $750$900,000 in fiscal 2004, $475$900,000 in fiscal 2005, $200$200,000 in fiscal 2006, and $200$233,000 in fiscal 2007.

        In August 2001, FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations". This standard addresses financial accounting2007 and reporting for obligations related to the retirement of tangible long-lived assets and the related asset retirement costs. SFAS No. 143 is effective for the

4

Company's$57,000 in fiscal year beginning January 1, 2003. The Company has not quantified the impact resulting from the adoption of this standard.

        In October 2001, FASB issued SFAS No. 144, "Accounting for Impairment or Disposal of Long-Lived Assets". The standard addresses financial accounting and reporting for the impairment or disposal of long-lived assets. There was no financial statement impact as a result of the Company's adoption of SFAS No. 144 on January 1, 2002.

        In April 2002, FASB issued SFAS No. 145, "Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections." The standard updates and simplifies the existing accounting pronouncements. SFAS No. 145 is effective for Company's fiscal year beginning January 1, 2003. The Company has not quantified the impact resulting from the adoption of this standard.

        In July 2002, FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities." The standard addresses accounting and reporting associated with exit or disposal activities. SFAS No. 146 is effective for the Company's fiscal year beginning January 1, 2003. The Company has not quantified the impact resulting from the adoption of this standard.2008.

B.    SHORT TERM INVESTMENTSE.    GOODWILL

        At June 30, 2002March 31, 2003 and December 31, 2001, short-term investments2002, goodwill by operating segment consisted of the following:

        Maturities of short-term investments are due within one year.

5

C.    INVENTORIES

        At June 30, 2002 and December 31, 2001, inventories consist of the following:

D.    NOTES RECEIVABLE

        In February 2002, pursuant to a Term Loan Agreement, the Company loaned $1.5 million to GenOdyssee, S.A., a French limited company located near Paris. The loan proceeds are to be used by GenOdyssee for general corporate purposes. The loan carries an annual interest rate of 5% and all accrued interest and principal are due on the earlier of January 31, 2003, or the first closing date of a "qualified offering" defined as the issuance of new voting equity securities in GenOdyssee pursuant to a private or public offering that raises gross proceeds of not less than $5 million. GenOdyssee may prepay this debt in whole or in part at anytime. GenOdyssee may make repayment of the principal and accrued interest in one of the following forms:

•

Shares of GenOdyssee issued as the same type and class and under the same terms and conditions, including share price, as shares issued in a "qualified offering".



•

Shares of GenOdyssee issued based on an independent third party appraisal in the event that a "qualified offering" is not consummated prior to January 31, 2003, or



•

Cash.

        In April 2002, pursuant to a Loan and Security Agreement, the Company loaned $0.35 million to Trivera Biotechnology, LLC, located in Ann Arbor, Michigan. The loan proceeds are to be used by Trivera for general corporate purposes. The loan carries an annual interest rate of 6%. The initial term of the loan is 12 months with automatic renewals for successive 6 month terms through April 30, 2007 unless the Company provides written notice of intent not to renew 15 days prior to the end of the initial or any renewal term. All accrued interest is payable in cash and due at the end of the initial term and any subsequent renewal term. The outstanding principal balance is due at the end of the initial term or the last renewal term. Trivera may make repayment of the principal in one of the following forms:

•

Cash,



•

At the sole election of the Company, voting securities of Trivera equal to 19.9% of the total ownership shares after issuance, or



•

A combination of cash and voting securities.

6

E.F.    STOCKHOLDERS' EQUITY AND STOCK OPTIONS

        Other Comprehensive Income.    Results of operations for the Company's foreign subsidiarysubsidiaries are translated using the average exchange rates during the period. Assets and liabilities are translated at the exchange rate in effect on the balance sheet dates. These translation adjustments, along with unrealized gains and losses on available-for-sale securities, are the Company's only components of other comprehensive income.

        Stock Options.    During the six months ended June 30, 2002,first quarter of fiscal 2003, the Company granted 306,0001,500 options with an exercise prices ranging from $6.16 to $9.63price of $1.98 per share. Of the total granted during the first six months, 20,000 options were granted to non-employees under consulting and other service agreements and compensation expense of approximately $51 was recorded associated with these grants. These expense amounts were calculated using the Black-Scholes option pricing model with the following assumptions: no common stock dividends, risk-free interest rate of 3.10%, volatility of 85%, and an expected option life of 1.5 years.

The following table summarizes activity under the 1997 Stock Option Plan during the sixthree months ended June 30, 2002.March 31, 2003.

        The weighted average fair value of options granted duringwas $1.12 for the first sixthree months of fiscal 2002 was $4.27 per share.2003. At June 30, 2002,March 31, 2003, the weighted average remaining contractual life of options outstanding was 7.06 years. The fair value of each stock option granted is estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for options granted in the first sixthree months of fiscal 2002:2003: no common stock dividends; risk-free interest ratesrate of 5.07%3.9%; 85% volatility; and an expected option life of 3 years.

7

        Pro forma net loss and loss per share for the six months ended June 30, 2002 and 2001, assuming compensation expense for the Stock Option Plan had been determined under SFAS 123, is as follows:

F.G.    INCOME TAXES

        Due to the Company's cumulative losses in recent years, expected losses in future years and inability to utilize any additional losses as carrybacks, the Company has not provided for an income tax benefit during the three months or six months ended June 30, 2002,March 31, 2003, based on management's determination that it was more likely than not that such benefits would not be realized. The Company will continue to assess the recoverability of deferred tax assets and the related valuation allowance. To the extent the Company begins to generate income in future periods and it determines that such valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized at such time. During the three months and six months ended June 30, 2002,March 31, 2003, the Company recorded current tax expense related to its Japan branch operations.

6

        As of June 30, 2002,March 31, 2003 and December 31, 2001,2002, the Company's deferred tax assets were offset by a valuation allowance of approximately $17.5$24.6 million and $14.7$23.2 million, respectively, due to the Company's cumulative losses in recent years, expected losses in future years and inability to utilize any additional losses as carrybacks.

G.    ACQUISITIONSH.    OPERATING SEGMENT AND SALE OF ASSETSGEOGRAPHIC INFORMATION

        Effective May 1, 2001,The Company's operations are managed based upon the nature of the products and services provided. Accordingly, the Company acquired Annovis, Inc,has determined that it operates in two segments, BioSystems and Nucleic Acids. Operations for these segments are evaluated based upon specific identification of revenues and expenses associated with the business activities resulting in a privately held company,segment operating income. Expenses that cannot be directly identified to an operating activity or are considered corporate overhead are not allocated to the segments in arriving at operating income for approximately $16.9the segment. Generally, decisions regarding asset allocation, financing, taxes or other items impacting the Company's balance sheet are made at the corporate level and, accordingly, operating segment balance sheet information is not typically reviewed by operating segment.

        The BioSystems operating segment generates revenue from the sale of automated instrument systems and associated consumable products and services. This segment's products are based upon separations chemistries and enzymology. Specifically, this segment's main products are the WAVE system, related bioconsumables and research services.

        The Nucleic Acids operating segment generates revenue from the sale of products and services based upon nucleic acid chemistries, separations chemistries and enzymology. Specifically, this segment's main products are nucleic acid building blocks or phosphoramidites, oligonucleotides, fluorescent markers, dyes and associated reagents and novel chemistry and process development services.

        The following is information for net sales and operating income by segment.

        Fixed asset additions during the quarter were mainly in the Nucleic Acid operating segment. Fixed assets in this segment were $12.3 million throughat March 31, 2003 and $8.9 million at December 31, 2002.

7

I.    CORPORATE RESTRUCTURING AND ADDITIONAL FINANCING

        The Company has historically experienced net losses and negative cash flows from operations. As a result, management formulated a restructuring plan designed to reduce expenses thereby better aligning the issuanceCompany's expense structure with current business prospects. The plan includes employee terminations, office closures, termination of approximately 1.9collaborations and write-offs of abandoned intellectual property. A significant portion of the plan was executed in the fourth quarter of 2002 resulting in the recording of $3.3 million sharesin restructuring charges. Restructuring activities continued in the current quarter resulting in additional restructuring charges of $264,000. Additional restructuring charges totaling between $235,000 and $435,000 are expected in the second quarter of 2003. The Company had accrued expenses and other liabilities associated with the restructuring activities of $730,000 at March 31, 2003 and $1.4 million at December 31, 2002. The accrued expenses at March 31, 2003 were primarily related to office closures. The accrued expense at December 31, 2002 were primarily related to office closures and employee severance.

        In March 2003 the Company entered into a loan commitment agreement with a financial institution for a secured line of credit up to a maximum commitment of $5.0 million. Collateral for the line of credit consists of all assets of Transgenomic, Inc. common stock,Funds available under the paymentline are equal to 80% of approximately $0.6 millioneligible accounts receivable balances. Management expects to finalize the line of credit agreement in cash in lieuthe second quarter of common stock to certain Annovis stockholders, and2003. The proposed term of the paymentagreement is 1 year carrying an interest rate of approximately $3.2 million of direct acquisition-related expenses. The acquisition was structured2.25% over prime. Management believes, as a merger of Annovis with a subsidiaryresult of the Companyrestructuring activities, current cash balances and resulted in Annovis becoming a wholly-owned subsidiaryfunds available from the secured line of the Company. Included in the total purchase price are costs relatedcredit will be sufficient to the Company's plan to close the Aston, Pennsylvania, facility and consolidate thosefund operations in Omaha, Nebraska. The anticipated costs to consolidate these operations total $.45 million and consist of employee severance payments, relocation expenses, fixed asset write-offs and other facility closure costs. Annovis is a specialty chemicals company that develops, manufactures and markets a wide variety of nucleic acid based products and service for the life sciences industry. Annovis's results of operations have been included in the accompanying financial statements beginning on May 1, 2001.

        The Company accounted for this transaction as a purchase. The Company has allocated the excess of the purchase price over the net assets acquired to goodwill. The costs assigned to intangible assetsthrough at least fiscal year 2003.

8

are being amortized on a straight-line basis over a period averaging 10 years. As of June 30, 2002, all identifiable tangible and intangible assets acquired and liabilities assumed have been allocated a portion of the cost equal to their estimated fair values based upon an appraisal from an independent appraiser as follows:

        The costs assigned to goodwill have been amortized through December 31 2001, on a straight-line basis over a period of 10 years. On January 1, 2002, the Company implemented Statement of Financial Accounting Standard No. 142. Under these new guidelines goodwill is no longer amortized. The Company's unaudited pro forma results of operations for the six months ended June 30, 2001, assuming the acquisition of Annovis, Inc. occurred as of the beginning of the periods presented are as follows:

        The unaudited pro forma results of operations are not necessarily indicative of the actual results of operations had the acquisition occurred on the dates indicated nor are they indicative of the results of operations for future periods.

9

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

        The following discussion should be read in conjunction with our consolidated financial statements and notes included elsewhere in this filing.

Overview

        We provide innovative solutionsproducts and services for the synthesis, purification and analysis of nucleic acids. Our solutionsproducts and services include automated instrument systems, associated consumables, andnucleic acid chemical building blocks, nucleic acid synthesis products, novel chemistry development for nucleic acid synthesis.acids, process development services and genetic variation discovery services. Our technologies center around three core competencies: separation chemistries, enzymology, and nucleic acid chemistries. We develop, assemble, manufacture and market our products and services to the life sciences industry to be used in research focused on molecular genetics of humans and other organisms. Such research could lead to development of new diagnostics and therapeutics. Our products can be used to analyze DNA or RNA at the molecular level, amplify, separate, and isolate nucleic acid fragments of particular interest and synthesize conventional or chemically-modified nucleic acid molecules. These capabilities are central to research seeking to discover and understand variations in the genetic code, the relationship of these variations to disease and, ultimately, to develop diagnostics and therapeutics based on this understanding. Our business plan is to participate in the value chain associated with these activities by providing key technology, tools, consumables, and biochemical reagents to those entities engaged in basic biomedical research and the development of diagnostics and therapeutic agents.

        RevenuesThe Company's operations are generatedmanaged based upon the nature of the products and services provided. Accordingly, the Company has determined that it operates in two segments, BioSystems and Nucleic Acids. Operations for these segments are evaluated based upon specific identification of revenues and expenses associated with the business activities resulting in a segment operating income. Expenses that cannot be directly identified to an operating activity or are considered corporate overhead are not allocated to the segments in arriving at operating income for the segment.

        The BioSystems operating segment generates revenue from the sale of our principalautomated instrument systems and associated consumable products and services. This segment's products are based upon separations chemistries and enzymology. Specifically, this segment's main products are the WAVE Systemsystem, related bioconsumables and our consumable products.research services. Since the WAVE System product introduction in 1997, we have sold over 830nearly 1,000 instruments to customers in over 30 countries. Revenues

        The Nucleic Acids operating segment generates revenue from the sale of consumable products increased significantly during the second quarter of 2002, due largely to our acquisition of Annovis, Inc. discussed below, and represented approximately 55% of our net sales as compared to approximately 37% in 2001.

        Before July 1, 1997, we manufactured and sold instruments and other products used in the non-life sciences instrumentation industry through our predecessor company, CETAC Holding Company, Inc. and its subsidiaries. On July 1, 1997, we merged these companies into Transgenomic, Inc., a new Delaware corporation, for the purpose of developing, manufacturing and selling our new life sciences product line in addition to continuing to manufacture and market our existing non-life sciences products. In 1999, we decided to focus our resources on our life sciences product line. Accordingly, during the second quarter of 2000 we sold the assets related to our non-life sciences instrument products. These assets consisted of inventory, property, plant and equipment, patents, other intellectual property rights and a lease deposit. Financial information for periods ending before the effective date of the sale, April 1, 2000, includes the results of our non-life sciences instrument product line. On July 21, 2000, we completed our initial public offering, selling 5,152,000 shares of common stock at $15.00 per share for net proceeds of approximately $69.9 million. In May 2001, we acquired Annovis, Inc., a specialty chemicals company that develops, manufactures and markets a wide variety of nucleic acid-based products and services for the life science industry, for a total purchase price of approximately $16.9 million.based upon nucleic acid chemistries, separations chemistries and enzymology. Specifically, this segment's main products are nucleic acid building blocks or phosphoramidites, oligonucleotides, fluorescent markers, dyes and associated reagents and novel chemistry and process development services.

        We have incurred significant losses resulting principally from costs incurred in research and development and selling, general and administrative costs associated with our operations. At June 30, 2002,March 31, 2003, we had an accumulated deficit of $35.7$53.4 million. Although weWe expect to continue to incur substantial research and development and selling, general and administrative costs as we continue to expand our operations we also expect these costs as a percentage of sales to decline.costs.

10

Critical Accounting Policies

        Accounting policies used in the preparation of the consolidated financial statements may involve the use of management judgments and estimates. Certain of the Company's accounting policies are considered critical as they are both important to the portrayal of the Company's financial statements and they require significant or complex judgments on the part of management. Our judgementsjudgments and estimates are based on experience and assumptions that we believe are reasonable under the

9

circumstances. Further, we evaluate our judgementsjudgments and estimates from time to time as circumstances change. Actual financial results based on judgment or estimates may vary under different assumptions or circumstances.

        The following areCompany considers its critical accounting policies that may involve the use of judgment or estimates.

        Allowance for Doubtful Accounts    Accounts receivable are shown net of an allowance for doubtful accounts. In determining an allowance for doubtful accounts, we consider the following.to be:

•

the age of the accounts receivable,Allowance For Doubtful Accounts



•

customer credit history,Inventories



•

customer financial information,



•

reasons for non-payment, and



•

our knowledge of the customer.

        If our customers' financial condition were to deteriorate, resulting in a change in their ability to make payment, additional allowances may be required.

        Inventories    Inventories are stated at the lower of cost (first-in, first-out method) or market. The Company has certain finished goods inventory it provides as demonstration units to potential customers for evaluation, as well as to certain universities and original equipment manufacturers for testing and demonstration. All demonstration units are held for resale and included in inventory at the lower of cost or market. Demonstration inventory that is greater than one year old and remains held for resale is reclassified from current assets to long-term assets and carried at the lower of cost or market. If the customer or institution does not purchase the instrument, it is retrieved, and, if necessary, reconditioned for sale. Demonstration inventory is evaluated for impairment based on its physical condition and technological status. No impairment loss has been recognized to date. At the time these instruments no longer are held for resale and will be used for in-house testing, analysis and training, they are transferred from inventory to property at the lower of cost or market and depreciated.

Depreciation and Amortization of Long-LivedLong-lived Assets    The Company's long-lived assets consist primarily

        For additional discussion of these critical accounting policies, see the "Management Discussion and equipment, goodwill, patents, intellectual property and capitalized software development costs. We believe the useful lives we assigned to these assets are reasonable. If our assumptions about these assets change as a result of events or circumstances and we believe the assets may have declined in value we may record impairment charges resulting in lower profits. Property and equipment are carried at cost. Depreciation and amortization are computed by the straight-line and accelerated methods over the estimated useful livesAnalysis" section of the related assets ranging from 3 to 7 years. The Company capitalizes the external and in-house legal costs and filing fees associated with obtaining patentsCompany's 2002 Annual Report on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued. Intellectual property, which is purchased technology, is recorded at cost and is amortized over its estimated useful life of between 5 and 10 years.

        Impairment of Long-Lived Assets    The Company evaluates goodwill for impairment on an annual basis. The Company assesses the recoverability of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in management's estimate of future undiscounted and discounted cash flows to determine recoverability of these assets. If management's

11

assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss. No impairment loss has been recognized to date.

        Income Taxes    Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. A valuation allowance has been provided for our remaining deferred tax assets due to the Company's cumulative losses in recent years, expected losses in future years and an inability to utilize any additional losses as carrybacks. The Company will continue to assess the recoverability of deferred tax assets and the related valuation allowance. To the extent the Company begins to generate income in future years and it is determined that such valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized at such time.

        Revenue Recognition    Revenue on the sales of products is recognized in accordance with the terms of the sales arrangement, which is generally based on receipt of an unconditional customer order and shipment of product. Our sales terms do not provide for the right of return unless the product is damaged or defective. Revenues from certain services associated with our research instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument.Form 10-K.

Results of Operations

Three Months Ended June 30,March 31, 2003 and 2002 and 2001

        Net Sales.    Net sales decreased 1%, from3% to $9.5 million in 2001 to $9.4 million in 2002. The decrease was the result of decreased sales of our WAVE systems offset by increased sales of consumable products. Total consumable sales increased 44%,2003 from $3.6 million in 2001 to $5.2$9.8 million in 2002. Sales of consumablesin our BioSystems operating segment increased largely due13% to sales of specialty chemical products added through the acquisition of Annovis in May, 2001. Specialty chemical product revenues increased 55% from $2.4$6.9 million in 2001 to $3.72003 from $6.1 million in 2002. Total revenues from sales of WAVE Systems decreased 29%, from $5.9increased 9% to $5.3 million in 2001 to $4.22003 from $4.9 million in 2002. The decreaseBioconsumable product sales included in this operating segment increased 29% to $1.6 million in 2003 from $1.2 million in 2002. Sales in our Nucleic Acid operating segment decreased 31% to $2.6 million in 2003 from $3.7 million in 2002. Sales of WAVE systemsystems increased mainly due to strong sales was seen mainly in Europe and the Far East offset by lower sales volumes to commercial and industrial customers and our North American customer base and our commercial and industrial customer base. SystemsIn the first quarter of 2003 we sold to our North American customers accounted for approximately 22% of system placements during the quarter as compared to between 40% to 50% ofno systems placements in fiscal years 2000 and 2001. Ourto commercial and industrial customers compared to approximately 8% of unit sales in 2002. Systems sold in North America accounted for approximately 2%24% of our system placements during the quarterunit sales in 2003 as compared to between 25%approximately 39% in 2002. Sales of WAVE related consumable products increased as the installed base of WAVE Systems has increased and as researchers begin to 35%use them more extensively in place of system placementsother methods of DNA analysis. The decrease in fiscal years 2000nucleic acid product sales is attributable largely to declines in demand for standard chemical building blocks. Demand for the development and 2001.production of novel chemistries has remained constant. Part of our business strategy is to position ourselves as a unique partner to biopharmaceutical and pharmaceutical companies in the early stages of their efforts to develop genomic-based diagnostics and therapeutics. As part of this strategy we are focusing our sales efforts on large consumers of our Synthetic Nucleic Acid products who are willing to commit to long-term supply agreements. While we expect to see increased sales of these products based upon this strategy, we also may see varying demand depending on the success of the biopharmaceutical and pharmaceutical companies on which we are targeting our sales efforts. Therefore, we may see large variations in quarterly revenue flows for these products.

        Cost of Goods Sold.    Cost of goods sold increased 10% from $4.123% to $5.8 million in 2001 to $4.62003 from $4.7 million in 2002. Cost of goods sold represented 43%2002, representing 61% of net sales in 2001, as2003 and 48% of net sales in 2002. BioSystems sales margins and average selling prices were consistent year over year. During the remainder of 2003 we anticipate that our cost of goods sold for our BioSystems products will remain within historical averages or improve slightly. Currently our Nucleic Acid products are sold at lower margins compared to 48%our Biosystems products. The margins in 2002.our Nucleic Acids operating segment are lower due to bulk sales of nucleic acid building block products and higher manufacturing costs due largely to our plant expansion efforts in Glasgow, Scotland and Boulder, Colorado. Both total cost of goods sold and cost of goods sold as a percent of sales increased year over year due to the mix of products sold. Currently our specialty chemical consumable products, which have become a larger component of our total revenues, are sold at lower margins as comparedand additional manufacturing costs related to our WAVE systems. Our WAVE systemsnew production facility in Boulder, Colorado. Overall we

10

anticipate that our total cost of goods sold represented 38%will be consistent with 2002 or slightly higher. This is the result of net salesthe underutilization of our new oligonucleotide production facility in 2001 as compared to 36% in 2002. WAVE systemsBoulder, Colorado. After 2003, we anticipate that the overall cost of goods sold as a percent of sales decreased year over year due to increased sales of our higher margin high throughput system along with the recognition of deferred revenue. Our consumables cost of goods sold represented 52% of net sales in 2001 as compared to 59% in 2002. Our specialty chemical consumable product margins are lower as compared to the prior year mainly due to the following factors, (1) bulk sales pricing to large customers under supply contracts and (2) increased raw material prices. We continue to expand our production capabilities in order to leverage our fixed costs into higher production volumes. We anticipate that this percentage will improve in the future as

12

we refine our systems configurations potentially reducing material costs, as we move to larger scaleimprove upon production ofmethods in our specialty chemicalsNucleic Acid operating segment which currently result in higher overall manufacturing costs and as consumable salesproduct revenues increase thereby spreading our fixed production costs over a larger revenue base.

        Selling, General and Administrative Expenses.    Selling, general and administrative expenses increased 9%, from $5.4decreased 22% to $4.6 million in 2001 to2003 from $5.9 million in 2002. The increaseThis decrease is primarily the result of higherour restructuring activities that have reduced personnel and personnel-related expenses, depreciationoutside services, rent and bad debt expense offset by a reduction in goodwill amortization, professional services andtravel related costs. Additionally, we recorded foreign currency transaction exchange rate gains.gains during the quarter. Combined these items accounted for over 90% of the total increase.    Direct personneldecrease. Total selling, general and personnel relatedadministrative expenses increasedrepresented 48% of net sales in 2003 versus 60% of net sales in 2002. It is expected that, as a result of our expanded employee base. Our employee base has increased largely due to the acquisition of Annovis. Depreciation expense has increased due to the acquisition of Annovis and investments in corporate infrastructure assets. Bad debt expense increased as management felt it was appropriate to increase the allowance for bad debt given the Company's increased level of accounts receivable. The decrease in goodwill amortization is the result of the Company adopting Statement of Financial Accounting Standards (SFAS) No.142,Goodwill and Other Intangible Assets. Selling, general and administrative expenses as a percent of net sales was approximately 57% in 2001 and 63% in 2002. While we anticipaterestructuring activities described below, our selling, general and administrative expenses to increase, in absolute dollars, over the next several years to support our growing marketing, sales and business activities we expect that these expenses will decline as a percentage of sales.decrease from 2002 levels.

        Research and Development Expenses.    Research and development expenses increased 36%, from $2.2decreased 16% to $2.3 million in 2001 to $3.02003 from $2.8 million in 2002. The increase in these expenses is attributable to increased personnel and personnel related expenses, depreciation and professional service fees. Direct personnel expenses accounted for approximately 77% of the total increase and were due to our expanded employee base. Professional service fees increased as the Company has engaged consultants and collaborators to supplement the activities of our internal research and development personnel. Other increases were attributable to the costs associated with the expanded activities of the staff and the Annovis operations and were offset by amounts capitalized related to the development of software to be used to operate our WAVE systems. During the quarter we capitalized approximately $460,000 in costs related mainly to the development of WAVE Navigator software which reached technological feasibility in the prior year. Research and development expenses consist of salaries and related personnel costs of researchers and software developers, material costs for prototypes and test units, legal expenses relating to intellectual property research and application development activities, testing and enhancement of our products, and amortization of intellectual property. We expense our research and development costs in the year in which they are incurred with the exception of certain capitalized software development costs. The decrease is the result of our restructuring activities that have reduced personnel and personnel-related expenses, outside services, supplies and travel related costs. These decreased expenses were offset by a decline in the amount of capitalized software development costs. Combined these items accounted for approximately 85% of the total decrease. Total research and development expenses represented approximately 23%24% of net sales in 2001 and approximately 32%2003 versus 28% of net sales in 2002. While we expectIt is expected that, as a result of our restructuring activities discussed below, our research and development spending to increase, in absolute dollars, over the next several years as we expand our development efforts we expect that these expenses will decline as a percentage of sales.decrease from 2002 levels.

        Stock Based Compensation.    Stock based compensation expense was $52,000$35,000 in 2001 and $35,0002003 as compared to $25,000 in 2002. This expense reflectsrepresents the amortization of deferred compensation related to stock options issued.

        Restructuring Charges.    During the fourth quarter of 2002 management formulated and executed a significant portion of a restructuring plan. The plan was developed to reduce expenses thereby better aligning the Company's expense structure with current business prospects. The plan included employee terminations, office closures, termination of collaborations and write-offs of abandoned intellectual property. We continued to execute upon the plan during the first quarter of 2003. As a result, $264,000 in restructuring charges were recorded and are included in operating expenses. These charges consisted mainly of employee severance costs. We expect that, as a result of the restructuring, our total operating expenses for 2003 will be 20% to 25% below 2002 levels. Further restructuring activities are expected in the second quarter of 2003. As such, additional restructuring charges totaling between $235,000 and $435,000 are expected.

Other Income.Income (Expense).    Other income and expense, which consists mainly of net interest income and other expense, declineddecreased to an expense of $41,000 in 2003 from $585,000 in 2001 to $155,000income of $237,000 in 2002. Interest income for the quarter was $161,000$34,000 as compared to $610,000$251,000 in 2001.2002. Interest expense for the quarter was $42,000 as compared to none in 2002. The decrease in interest income is a result of declining interest rates on investments and reductions in our short term investmentsshort-term investment balances. Interest expense will increase in 2003 due to the long-term debt obtained by the Company during 2002 and the recently committed line of credit.

11

        Income Taxes.    NoIncome tax expense during the quarter was $14,000 while in 2002 income tax benefitexpense was $21,000. During the quarter the Company recorded incurrent tax expense related to its Japan branch operations and certain state taxes. Our deferred tax assets as of March 31, 2003 were $24.6 million and were offset by a valuation allowance of $24.6 million. Our deferred tax assets as of December 31, 2002 or 2001.were $23.2 million and were offset by a valuation allowance of $23.2 million. No further tax benefits are being recorded due to our cumulative losses in recent years, expected losses in future years and the uncertainty as to whether we will be able to utilize any additional losses as carrybacks. During the three months ended June 30, 2002, the Company recorded current tax expense related to its Japan branch operations and wrote off certain state tax credits that are no longer collectible. We will continue to assess the recoverability of deferred tax assets and the related valuation allowance. We expect to continue to incur losses and expect to continue to provide valuation allowances against deferred tax assets. To the extent we begin to generate income in future years and it is determined that such

13

valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized.

Six Months Ended June 30, 2002 and 2001

        Net Sales.    Net sales increased 10%, from $17.5 million in 2001 to $19.3 million in 2002. The increase was the result of increased sales of consumable products offset by decreased sales of our WAVE system. Total consumable sales increased 106%, from $4.9 million in 2001 to $10.1 million in 2002. Sales of consumables increased largely due to sales of specialty chemical products added through the acquisition of Annovis in May, 2001. Specialty chemical product revenues increased 204% from $2.4 million in 2001 to $7.3 million in 2002. Total revenues from sales of WAVE Systems decreased 27%, from $12.6 million in 2001 to $9.1 million in 2002. The decrease in WAVE system sales was seen mainly in our North American customer base and our commercial and industrial customer base. Systems sold to our North American customers accounted for approximately 27% of system placements during the first six months as compared to between 40% to 50% of systems placements in fiscal years 2000 and 2001. Our commercial and industrial customers accounted for approximately 5% of our system placements during the first six months as compared to between 25% to 35% of system placements in fiscal years 2000 and 2001.

        Cost of Goods Sold.    Cost of goods sold increased 19% from $7.8 million in 2001 to $9.3 million in 2002. Cost of goods sold represented 45% of net sales in 2001, as compared to 48% in 2002. Both total cost of goods sold and cost of goods sold as a percent of sales increased year over year due to the mix of products sold. Currently our specialty chemical consumable products, which have become a larger component of our total revenues, are sold at lower margins as compared to our WAVE systems. Our WAVE systems cost of goods sold represented 42% of net sales in 2001 as compared to 36% in 2002. WAVE systems cost of goods sold as a percent of sales decreased year over year due to increased sales of our higher margin high throughput system along with the recognition of deferred revenue. Our consumables cost of goods sold represented 52% of net sales in 2001 as compared to 59% in 2002. Our specialty chemical consumable product margins are lower as compared to the prior year mainly due to the following factors, (1) bulk sales pricing to large customers under supply contracts and (2) increased raw material prices. We continue to expand our production capabilities in order to leverage our fixed costs into higher production volumes. We anticipate that this percentage will improve in the future as we refine our systems configurations potentially reducing material costs, as we move to larger scale production of our specialty chemicals and as consumable sales increase thereby spreading our fixed production costs over a larger revenue base.

        Selling, General and Administrative Expenses.    Selling, general and administrative expenses increased 24%, from $9.6 million in 2001 to $11.8 million in 2002. The increase is the result of higher personnel and personnel-related expenses, depreciation and bad debt expense offset by a reduction in goodwill amortization, professional services and foreign currency exchange rate gains. Combined these items accounted for over 90% of the total increase.    Direct personnel and personnel related expenses increased as a result of our expanded employee base. Our employee base has increased largely due to the acquisition of Annovis. Depreciation expense has increased due to the acquisition of Annovis and investments in corporate infrastructure assets. Bad debt expense increased as management felt it was appropriate to increase the allowance for bad debt given the Company's increased level of accounts receivable. The decrease in goodwill amortization is the result of the Company adopting Statement of Financial Accounting Standards (SFAS) No.142,Goodwill and Other Intangible Assets. Selling, general and administrative expenses as a percent of net sales was approximately 55% in 2001 and 61% in 2002. While we anticipate selling, general and administrative expenses to increase, in absolute dollars, over the next several years to support our growing marketing, sales and business activities we expect that these expenses will decline as a percentage of sales.

14

        Research and Development Expenses.    Research and development expenses increased 35%, from $4.3 million in 2001 to $5.7 million in 2002. The increase in these expenses is attributable to increased personnel and personnel related expenses, depreciation and professional service fees. Direct personnel expenses accounted for approximately 85% of the total increase and were due to our expanded employee base. Professional service fees increased as the Company has engaged consultants and collaborators to supplement the activities of our internal research and development personnel. Other increases were attributable to the costs associated with the expanded activities of the staff and the Annovis operations and were offset by amounts capitalized related to the development of software to be used to operate our WAVE systems. During the first half of 2002 we capitalized approximately $990,000 in costs related mainly to the development of WAVE Navigator software which reached technological feasibility in the prior year. Research and development expenses represented approximately 24% of net sales in 2001 and approximately 30% of net sales in 2002. While we expect research and development spending to increase, in absolute dollars, over the next several years as we expand our development efforts we expect that these expenses will decline as a percentage of sales.

        Stock Based Compensation.    Stock based compensation expense was $85,000 in 2001 and $60,000 in 2002. This expense reflects the amortization of deferred compensation related to stock options issued.

        Other Income.    Other income, which consists of net interest income and other expense, declined from $1.5 million in 2001 to $405,000 in 2002. Interest income for the first six months of 2002 was $423,000 as compared to $1.5 million in 2001. The decrease in interest income is a result of declining interest rates on investments and reductions in our short term investments balances.

        Income Taxes.    No income tax benefit was recorded in 2002 or 2001. No further tax benefits are being recorded due to our cumulative losses in recent years, expected losses in future years and the uncertainty as to whether we will be able to utilize any additional losses as carrybacks. During the six months ended June 30, 2002, the Company recorded current tax expense related to its Japan branch operations and wrote off certain state tax credits that are no longer collectible. We will continue to assess the recoverability of deferred tax assets and the related valuation allowance. We expect to continue to incur losses and expect to continue to provide valuation allowances against deferred tax assets. To the extent we begin to generate income in future years and it is determined that such valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized.

Liquidity and Capital Resources

        We have historically experienced net losses and negative cash flows from operations during the past three years.flows. As a result, we had an accumulated deficit of $35.7$53.4 million as of June 30, 2002. On July 21, 2000, we issued 5,152,000 shares of common stock in our initial public offering at $15.00 per share. After payment of the underwriters' discounts and commissions and other expenses, we received net proceeds of approximately $69.9 million from this offering. In addition, warrants and options to purchase shares of common stock have been exercised at various times since our initial public offering providing us with approximately $5.7 million in additional cash.March 31, 2003. As of June 30, 2002March 31, 2003, and December 31, 2001,2002, we had approximately $6.4 million and $19.6$9.7 million, respectively, in cash and cash equivalents. In addition, as of June 30, 2002 and December 31, 2001,2002, we had approximately $18.7$3.6 million and $23.9 million, respectively, in short-term investments for total cash and short-term investments of approximately $25.0$13.3 million.

        During the first quarter of 2003 our major cash expenditures were the funding of our operations and capital projects. A total of approximately $6.9 million of cash and $43.5investments was used with approximately $3.1 million respectively.used to fund our operations and $3.7 million for capital projects. Operating activities and capital projects were funded through existing cash and investments. Major capital projects during the quarter included facility build-out, expansion and improvement at our two nucleic acid production facilities in Boulder, Colorado and Glasgow, Scotland. The Boulder facility project is designed to be a cGMP (Good Manufacturing Practices) facility for the synthesis of oligonucleotides. This facility began non-GMP production operations during the first quarter of 2003 and is expected to begin cGMP production in the second quarter of 2003. The Glasgow facility project, which produces nucleic acid building blocks, included the upgrading of equipment and processes at the current production facility and the build-out of a new facility that will include significant capacity expansion along with further equipment and process improvements. The current production facility improvements were completed during 2002 and the first production line, or pilot line, in the new facility is expected to be completed in 2003.

        Our operating activities in the first six months resulted in net cash outflows of $10.4$3.1 million in 2002 as compared to $3.92003 and $4.7 million in 2001.2002. The operating cash outflows for these periods resulted mainly from our operating losses. Significant investments in research and development and sales and marketing contributed to the operating losses. Additionally, inventoryThe operating cash outflows for 2003 are lower than those in the prior year due in large part to increases in accounts payables and accrued liabilities offset by operating losses and increased accounts receivable balances. Accounts receivable balances increased as raw

15

materials, workdue largely to the concentration of sales during the fourth quarter of 2002 and first quarter of 2003 in process and finished goods inventory related to our specialty chemicals consumable products were increased as we continue to expand production capabilities and plan for production needs to fulfill long-term supply contracts.European countries where payment terms of 90 days or more are customary.

        Net cash used inprovided by investing activities was $157,000 in the first six months was $3.3 million in 20022003 as compared to $26.6cash used of $7.8 million for 2002. The investing cash flow in 2001. The cash2003 is due primarily to the maturity of short-term investment funds offset by investment in property, plant and equipment. Cash used in investing activities in 2002 was due primarily to our investment in property, plant and equipment, increased notes receivable and our increasenet reinvestment of funds in short-term investments. Property, plantinvestments and equipment increased in part due to the purchase of a production facility in Glasgow, Scotland, as discussed below. Notes receivable increased primarily as we entered into a convertible note agreement with Genodyssee S.A.. During the remainder of 2002 and 2003 we expect to continue to make significant investments in property, plant and equipment. Our capital expenditures budget for 2002 is approximately $13.0 to $15.0 million which includes $8.0 to $10.0 million for our synthetic nucleic acid product facility expansion project. Plans and budgets for our synthetic nucleic acid product production facility expansion project are being finalized and we currently expect the capital expenditures on this project to be in the $15.0 to $25.0 million range over the next 2 to 3 years. The facility expansion is being planned in anticipation of the expected growth in our synthetic nucleic acid products business.

        Net cash provided by financing activities was $33,000 in the first six months was $91,000 in 2002 compared to net cash used of $92,000 in 2001.2003 and $388,000 for 2002. The financing cash inflows in 2002 were the result of proceeds from the sale of common stock through the exercise of stock options, offset by the purchase of treasury stock. In June, 2002, our Board of Directors approved a program to repurchase up to one million shares of our common stock in the open market or in privately negotiated transactions for an aggregate cost of up to $5.0 million, subject to the restrictions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended, and other applicable securities laws. As part of that program, in an unsolicited private transaction on June 26, 2002, we purchased 232,700 shares of our common stock for approximately $437,000. We have entered into this program because we believe our current market valuation is below the Company's intrinsic value and growth prospects going forward. We have no set plan or formula governing when we may purchase additional shares. We will evaluate buying opportunities on a case-by-case basis.

        On May 21, 2002, as part of our synthetic nucleic acid production expansion project, we purchased a 45,000 square foot production facility in Glasgow, Scotland, for approximately $1.8 million in cash. In July, 2002, our Board of Directors authorized us to enter into a financing arrangement with a financial institution secured by the newly-purchased facility. The arrangement, which we expect to close in the near future, would provide us approximately $1.5 million and would bear a fixed annual interest rate of approximately 7%. It would be repayable in monthly installments over a 15 year term.12

        Additionally, weWe are party to a number of lease agreements mainly for office, research and development and production facilities. Such lease agreements expire at various dates through 2007, with future minimum annual lease payments of approximately $2.0 million.

        In February 2002, pursuant$2.8 million in 2003 declining to a Term Loan Agreement, the Company loaned $1.5 million to Genodyssee, S.A., a French limited company located near Paris. Genodyssee is a European genomics company that operates in two main divisions, one that is developing drug targets based on genetic variability and one that provides custom research services. The loan proceeds are to be used by Genodyssee for general corporate purposes. The loan carries an annual interest rate of 5% and all accrued interest and principal are due on the earlier of January 31, 2003, or the first closing date of a "qualified offering" defined as the issuance of new voting equity securities in Genodyssee pursuant to a private or public offering that raises gross proceeds of not less than $5 million. Genodyssee may prepay

16

this debt in whole or in part at anytime. Genodyssee may make repayment of the principal and accrued interest in one of the following forms:

•

Shares of Genodyssee issued as the same type and class and under the same terms and conditions, including share price, as shares issued in a "qualified offering",



•

Shares of Genodyssee issued based on an independent third party appraisal in the event that a "qualified offering" is not consummated prior to January 31, 2003, or



•

Cash.

        Genodyssee has been a customer of Transgenomic since July of 2000 purchasing multiple WAVE systems, system upgrades and consumable products. In addition, in December 2001, the Company and Genodyssee entered into a Service Provider Agreement. The Service Provider Agreement is a strategic alliance between Transgenomic and Genodyssee whereby Transgenomic will perform sales and marketing activities in the United States, Europe and Japan for certain analytical services related to nucleic acids which will be performed by Genodyssee. The Service Provider Agreement has an initial term of 3 years and automatically renews for successive 1 year periods until cancelled under the terms of the Agreement. In conjunction with the Service Provider Agreement, the Company entered into a $1.0 Million Revolving Line of Credit Agreement with Genodyssee. Genodyssee will utilize the Line of Credit in managing its cash flows and working capital needs to perform services under the Service Provider Agreement. The outstanding balance of the Line of Credit is not to exceed the lesser of $1.0 million or 25% of the total amount currently due to Genodyssee under customer contracts entered into under the Service Provider Agreement. The Line of Credit carries an annual interest rate of 5% and the same term as the Service Provider Agreement. As of June 30, 2002, there was no balance outstanding on the Line of Credit.

        In May 2001, we acquired Annovis, Inc., a specialty chemicals company that develops, manufactures and markets a wide variety of nucleic acid-based products and services for the life science industry, for a total purchase price of approximately $16.9 million. As part of the purchase price we issued approximately 1.9 million shares of common stock valued at $13.1 million. The remaining purchase price is made up of direct acquisition related expenses of approximately $3.2 million and cash paid in lieu of shares to certain Annovis stockholders of approximately $0.6 million.2007.

        We expect to devote substantial capital resources to continue our research and development efforts, to expand our marketing and sales and customer support activities, and for other general corporate activities. Our capital requirements for operations depend on a number of factors, including the level of our research and development activities, market acceptance of our products and services, the resources we devote to developing and supporting our products and services, normal capital expenditures and other factors. GivenThe restructuring plan developed in 2002 is expected to reduce our operating expenses and thereby reduce the current interest rate environment and the expected costs ofcash needed to fund our planned synthetic nucleic acid production expansion,operations until such time as we are currently investigating various financing vehiclesbecome cash flow positive. Additionally, our capital budget includes expenditures for the project, including a mortgage for the purchasecompletion of the building, as described earlier. Even if we complete our facility expansion usingprojects in Glasgow, Scotland, and Boulder, Colorado and for general facility and equipment improvements. Additional expansion projects for the Glasgow and Boulder production facilities may be incurred over the next 2 to 3 years as business demand dictates. During the second quarter 2003 we expect to continue to make significant investments in property, plant and equipment, however, in the second half of 2003 we expect our capital expenditures to drop significantly as our production expansion projects come to an end. Our original capital expenditures budget for 2003 was approximately $8.4 million. We have re-evaluated the budget and have revised it downward. We now expect capital expenditures for the full year to be in the range of $6.7 million to $7.4 million.

        We expect to meet total cash needs for the remainder of 2003 from existing cash as of March 31, 2003 of $6.4 million, additional cash generated from operations during 2003 and funds available to us under a new $5.0 million credit facility. In March 2003, we believeentered into a loan commitment agreement with a financial institution for up to a $5.0 million secured line of credit. Collateral for the line consists of all assets held by Transgenomic, Inc. Funds available under the line are equal to 80% of eligible accounts receivable balances. Management expects to finalize the line of credit agreement in the second quarter of 2003. The proposed term of the agreement is 1 year carrying a variable interest rate of 2.25% over prime. Additionally, we continue to pursue financing of up to an additional $5.0 million beyond the committed line of credit. We feel that our current cash balancessuch additional financing will be sufficientsecured in 2003. Current financial and cash flow projections indicate that operating cash flows are expected to fund operations through at least fiscal yearturn positive during the fourth quarter of 2003. DuringThese projections may or may not be realized based upon actual operating results and capital project requirements. Thus, during or after this period, if our existing cash and short-term investments, and cash generated by operations and available borrowings under credit agreements is insufficient to satisfy our liquidity requirement,requirements, we may need to sell additional equity or debt securities, or obtain additional credit arrangements. We cannot assure you that any financing arrangement will be available in amounts or on terms acceptable to us. Our failure to raise additional capital, if needed, would harm our financial condition, results of operations and our business.

Impact of Inflation

        We do not believe that price inflation had a material adverse effect on our financial condition or results of operations during the periods presented.

17

Recent Accounting Pronouncements

        In June 2001, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standard (SFAS) No. 141,Business Combinations, and SFAS No. 142,Goodwill and Other Intangible Assets. SFAS No. 141 requires all business combinations initiated after June 30, 2001 to be accounted for using the purchase method. SFAS No. 142 establishes new guidelines for accounting for goodwill and other intangible assets and provides that goodwill and other intangible assets with indefinite lives will not be amortized, but will be evaluated for impairment annually. The Company adopted SFAS No. 142 beginning January 1, 2002. The provisions of SFAS No. 142 also require the completion of a transitional impairment test within six months of adoption, with any impairments treated as a cumulative effect of a change in accounting principle. The Company has performed the transitional impairment tests and has determined that no impairment exists at the time of adoption of SFAS No. 142.

        In August 2001, FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations". This standard addresses financial accounting and reporting for obligations related to the retirement of tangible long-lived assets and the related asset retirement costs. SFAS No. 143 is effective for the Company's fiscal year beginning January 1, 2003. The Company has not quantified the impact resulting from the adoption of this standard.

        In October 2001, FASB issued SFAS No. 144, "Accounting for Impairment or Disposal of Long-Lived Assets". The standard addresses financial accounting and reporting for the impairment or disposal of long-lived assets. There was no financial statement impact as a result of the Company's adoption of SFAS No. 144 on January 1, 2002.

        In April 2002, FASB issued SFAS No. 145, "Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections." The standard updates and simplifies the existing accounting pronouncements. SFAS No. 145 is effective for Company's fiscal year beginning January 1, 2003. The Company has not quantified the impact resulting from the adoption of this standard.

        In July 2002, FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities." The standard addresses accounting and reporting associated with exit or disposal activities. SFAS No. 146 is effective for the Company's fiscal year beginning January 1, 2003. The Company has not quantified the impact resulting from the adoption of this standard.

Foreign Currency Rate Fluctuations

        Historically approximately 50% of our net sales have been to customers outside the United States. Most of these sales are completed by our wholly-ownedwholly owned subsidiaries, Transgenomic, Ltd. and Cruachem, Ltd., and are made in their operating currency, the British pounds sterling,Pounds Sterling, or the Euro. Results of operations for the Company's foreign subsidiaries are translated using the average exchange rate during the period. Assets and liabilities are translated at the exchange rate in effect on the balance sheet dates. To further limit our exposure to exchange rate risk all sales quotes issued by

13

Transgenomic, Ltd. are based upon the United States dollar pricing converted at prevailing exchange rates at the time of the quote. Additionally, such quotes have short expiration dates. As a result, although we are subject to exchange rate risk based largely upon the levels of outstanding accounts receivables, management feels we do not have a material exposure to foreign currency rate fluctuations at this time.

Forward-looking informationInformation

        This report contains a number of "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Many of these forward-looking statements refer to our plans, objective, expectations and intentions, as well as our future financial results. You can identify

18

these forward-looking statements by forward-looking words such as "expects," anticipates," "intends," "plans," "may," "will," "believes," "feels", "seeks," "estimates," and similar expressions. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Such factors would include the growth of the markets for DNA analysis technology and consumable products, the acceptance of our technology, our ability to continue to improve our products, and expand production capacity, the development of competing technologies, and our ability to protect our intellectual property rights.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

        The primary objectiveWe recently committed to a secured line of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Somecredit that carries a variable interest rate. This line of the securities that we invest in may have market risk. This means that a change in prevailing interest rates may cause the market value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the market value of our investmentcredit will probably decline. To minimize this risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, money market funds, government and non-government debt securities. The average duration of all of our investments in 2002 was less than one year. Due to the short-term nature of these investments, we believe we have no material exposureexpose us to interest rate risk arising fromin 2003. We no longer have short-term investments that subject us to the market risks described in our investments. Therefore,most recent Annual Report on Form 10-K.

Item 4.    Controls and Procedures

        A review and evaluation was performed by the Company's management, including the Company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing of this quarterly report. Based on that review and evaluation, the CEO and CFO concluded that the Company's current disclosure controls and procedures, as designed and implemented, were effective. There have been no quantitative tabular disclosure is presented.significant changes in the Company's internal controls subsequent to the date of their evaluation. There were no significant material weaknesses identified in the course of such review and evaluation and, therefore, no corrective measures were taken by the Company.

14

PART IIII. OTHER INFORMATION

Item 1.    Legal Proceedings

        We are not a party to, and none of our assets or properties are subject to, any material legal proceedings.

Item 2.    Changes in Securities and Use of Proceeds

d)

The amount of net proceeds from our initial public offering was approximately $69.9 million. Approximately $3.5 million of these net offering proceeds was used to repay outstanding indebtedness and approximately $4.6 million was used to acquire notes evidencing loans made by a bank to the Company owned by one of our directors that purchased the assets of our non-life sciences product line in May 2000. We used approximately $3.1 million of the net proceeds for capital expenditures during 2000, an additional $5.7 million during 2001, an additional $11.5 million during 2002 and an additional $4.5$3.7 million in the first sixthree months of 2002.2003. We expect to apply up to an additional $9.0 to $11.0$3.7 million of the net proceeds of this offering for capital expenditures during 2002.the remainder of 2003. Such expenditures were made for, and are expected to be made for, general infrastructure investments (i.e. computer equipment, software and leasehold improvements) and production facility improvements and expansion. At June 30, 2002,March 31, 2003, approximately $23.4$3.4 million was invested in cash equivalent investments and in short-term, investment-grade, interest-bearing securities.investments. We expect to use the remaining amount of the net offering proceeds for general working capital needs, including research and development and sales and marketing expenses.needs. The amounts actually expended for each purpose may vary significantly depending upon many factors, including future sales growth, the progress of our product development efforts and the amount of cash generated or used by our operations.

Item 4.    Submission of Matters to a Vote of Security Holders

        Our annual shareholder's meeting was held on May 22, 2002 for the purpose of electing a Class II director, and ratifying the appointment of Deloitte & Touche LLP as our independent accountants for the fiscal year ending December 31, 2002.None

        A total of 23,671,821 shares of our common stock were entitled to vote at the meeting and a total of 20,766,246 shares (87.73%) were represented at the meeting, in person or by proxy. The following sets for the results of the voting at the annual meeting:

1.

Election of Directors

Dr. Jeffrey Sklar            For—20,702,914            Withheld—63,332

2.

Ratification of the appointment of Deloitte & Touche LLP as independent auditors for the year ended December 31, 2002

For—20,418,881        Against—314,874        Abstain—32,491        Broker non-vote—0

        Further information regarding these matters is contained in our Proxy Statement dated April 19, 2002.

20

Item 6.    Exhibits and Reports on Form 8-K

(a)

Exhibits

15

(b)

Reports on Form 8-K

        The Registrant did not file a Report on Form 8-K during the quarter ended June 30, 2002.March 31, 2003.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

17

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Collin J. D'Silva, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Transgenomic, Inc. (the Registrant);



2.

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;



3.

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;



4.

The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and we have:



a)

Designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;



b)

Evaluated the effectiveness of the Registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and



c)

Presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;



5.

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):



a)

all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant's ability to record, process, summarize and report financial data and have identified for the Registrant's auditors any material weaknesses in internal controls; and



b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal controls; and



6.

The Registrant's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

18

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, William P. Rasmussen, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Transgenomic, Inc. (the Registrant);



2.

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;



3.

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;



4.

The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and we have:



a)

Designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;



b)

Evaluated the effectiveness of the Registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and



c)

Presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;



5.

The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):



a)

all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant's ability to record, process, summarize and report financial data and have identified for the Registrant's auditors any material weaknesses in internal controls; and



b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal controls; and



6.

The Registrant's other certifying officer and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

QuickLinks

Item 1. Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures

Item 1. Legal Proceedings
Item 2. Changes in Securities and Use of Proceeds
Item 4. Submission of Matters to a Vote of Security Holders
Item 6. Exhibits and Reports on Form 8-K